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declined from 76% to 31% as a share of all uses from 1994 to 2007, while substantial 
increases in use occurred for bipolar affective disorder (5% to 39%) and depression 
(8% to 15%). The fraction of atypical antipsychotic use for indications with insufﬁ -
cient evidence of efﬁ cacy increased from 32% in 1994 to 58% in 2007, representing
26 million prescriptions and $7.3 billion dollars in expenditures in 2007. During 2007, 
primary care physicians accounted for 21% of visits where an antipsychotic was
used, as compared with psychiatrists (77%) or physicians from other specialties 
(2%). Antipsychotic use in settings of insufﬁ cient evidence was similar among primary
care physicians and psychiatrists. CONCLUSIONS: The scope and costs of this 
expansion, due to both clinical innovation and overuse, demonstrate the importance
of efforts to limit the clinical application of antipsychotics to settings of sufﬁ cient 
evidence.
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OBJECTIVES: To validate adult ADHD prevalence estimates in a US health care
claims database. METHODS: A commercial research database (MarketScan from 
Thomson Reuters; employer clients only) was used to estimate the annual prevalence 
of adult ADHD from 2002 to 2007. Patients (18–64 years) diagnosed with ADHD 
(ICD-9) on at least 2 occasions within 12 months were counted in each year they 
had a diagnostic/drug claim indicating ADHD. These prevalence rates were compared
with rates from a US epidemiological study which estimated adult ADHD prevalence 
using clinical interviews of respondents (18–44 years) from the 2005 National Comor-
bidity Survey replication (NCS-R; Kessler et al, 2006). RESULTS: In MarketScan
the prevalence of diagnosed and treated ADHD in US adults was 1.24 per 1000 
members in 2002, increasing annually to more than triple in 2007 (4.02 per 1000). 
The proportion of females: males with ADHD increased yearly. Prevalence per 1000
grew faster among 18–24 than 25–64 year olds. ADHD with hyperactivity was more
prevalent than ADHD without hyperactivity. In contrast, the NCS-R study reported
a higher ADHD prevalence (44 per 1000) in 2005 in the 18–44 group, with more 
males than females diagnosed with ADHD. Prevalence estimates from our study 
increased when correcting for differences between studies in age range (18–64 versus 
18–44 years; 4.59 per 1000) and number of diagnoses (2 vs 1; 5.03 per 1000). In the
NCS-R study, only 10.9% of individuals who were diagnosed received treatment.
Thus, the number of treated patients in the NCR-S study (4.796 per 1000) is close to 
the 4.02 per 1000 reported from the claims database. CONCLUSIONS: The estimated 
prevalence of adult ADHD in diagnosed and treated patients based on claims data is 
similar to that based on clinical interviews, validating the use of claims data to estimate 
prevalence.
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OBJECTIVES: To evaluate the risk of injury associated with attention-deﬁ cit hyper-
activity disorder (ADHD) using information from an employee database. METHODS:
Using the MarketScan Commercial Claims and Encounters Database from Thomson 
Reuters, patients aged 18 to 64 years and diagnosed with ADHD (N  31,752) were 
matched by similarity in demographics and data availability 3:1 to controls without 
ADHD (N  95,256) or 1:1 to controls diagnosed with depression (N  29,965). 
Patients with ADHD were also stratiﬁ ed into compliant (Medication Possession Ratio 
[MPR] q0.8; N  8654), partially compliant (0.3 a MPR  0.8; N  5233) and non-
compliant (MPR  0.3; N  4007) cohorts. Risk of injury was compared between
groups for January to December 2006. Multivariate analyses controlled for treatment
differences between groups that remained after matching. RESULTS: Injury rates were 
higher in the ADHD group than in the non-ADHD control group (21.6% vs 15.7%,
p  0.001) and depression group (21.4% vs. 20.5%, p  0.0085), and higher in the 
compliant group than in the partially compliant (22.8% vs 20.3, p  0.0004) and 
noncompliant (22.8% vs 17.8%, p  0.001) groups. In multivariate analyses, risk of 
injury was higher in the ADHD group than in the non-ADHD (1.3194 odds ratio 
[OR], p  0.01) and depression control groups (1.1263 OR, p  0.01) and higher in
compliant and partially compliant patients than in noncompliant patients (1.2633 and
1.664 OR, respectively, p  0.01). Comorbid depression, anxiety and substance abuse 
predicted a higher risk of injury in the ADHD versus control groups (p  0.01) and 
in compliant/partially compliant patients versus noncompliant patients (p  0.01), with 
magnitude equal to or exceeding that of the ADHD group alone. CONCLUSIONS:
Patients with ADHD had higher risk of injury than similarly matched patients without 
ADHD or with depression, suggesting important implications for workplace safety
and liability.
PMH11
RISK ASSESSMENT OF POISONING WITH DRUGS OF THERAPEUTIC 
IMPORTANCE BY TOXICOVIGILANCE
Sam KG, Tunga G, Pandey S
Manipal University, Manipal, Karnataka, India
OBJECTIVES: Toxicovigilance studies were carried out with the aim to determine the
health hazards, treatment and outcome of therapeutic drug overdose. METHODS: All 
therapeutic drug poisoned patients admitted to a tertiary care South Indian hospital. 
were evaluated for predisposing factors manner of exposure, severity at admission,
treatment, hospitalization period, clinical status at discharge, , in order to implement 
medication safety programs. RESULTS: A total of 200 patients were admitted with 
therapeutic drug overdose. A total of 153 cases intentionally ingested the drugs, while 
29 cases had overdose during routine therapy, and 18 cases had ingested the drugs 
accidentally. Depression was the major predisposing factor for intentional self harm. 
Most of the poisoning with therapeutic drugs occurred due to intentional self harm n 
 153 (76.5%). Other manner of exposures include overdose during therapeutic use
n  29 (14.5%) or accidental exposure n  18 (9%). There was a signiﬁ cant (P 
0.001) association of employment and occupational status on the manner of exposure. 
The mean GCS, APACHE II scores, PMR and PSS for all the patients was 8.46 o 3.6; 
20.63 o 5.0; 38.58 o 16.1 and 2.96 o 0.79 (Mean o SD) respectively. The mean GCS 
score was signiﬁ cantly (P  0.033) different between various class of poisoning. The
APACHE II scores were not signiﬁ cantly (P  0.05) different between various drug 
classes. The mean severity scores was signiﬁ cantly (P  0.016) different between 
various class of drugs. The treatment provided was empirical and symptomatic with 
differing decontamination procedures. The average hospitalization period was 6.68 o
4.9 days with a median of 6 days range (3–8). Majority of them 189(94.5%) improved,
while 5 patients were discharged with severe sequele, and six patients expired during 
hospital stay. CONCLUSIONS: The extent of harm caused due to therapeutic drug 
poisoning can be minimized by systematically estimating the severity at triage and
providing treatment as per standardized guidelines.
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OBJECTIVES: The purpose of this study was to evaluate the relative efﬁ cacy and
safety of pregabalin and clonazepam in the treatment of anxiety disorders. METHODS:
A meta-analysis was performed with randomized clinical trials (RCTs) where pregaba-
lin or clonazepam were used for any anxiety disorders. Effectiveness was assessed with
the Hamilton Anxiety Rating Scale (HAM-A); safety with the frequency and type of 
adverse events (AEs). RCT were searched in July 2008 in Medline, EMBASE, PsycInfo, 
CINAHL and the Cochrane Collaboration. Two independent reviewers identiﬁ ed the 
abstracts, full articles, and then extracted data; results were compared and settled 
through consensus. RCT included both drugs and its comparison with placebo. Odds 
ratios and weighted means differences (WMD) were calculated. Both, ﬁ xed and 
random effects models were employed in the analysis. RESULTS: From 1893 abstracts, 
we obtained 40 RCT, 23 were excluded (unacceptable designs, insufﬁ cient outcome 
data, no placebo control) leaving 17. Seven pregabalin studies were used to evaluate 
its effectiveness and safety; four clonazepam studies for effectiveness and six for safety.
Clonazepam studies included panic disorder and social phobia. Six of seven pregabalin
studies were in generalized anxiety disorder and one for social anxiety disorder. We 
found that both drugs signiﬁ cantly diminished anxiety levels after four to 32 weeks 
of treatment. Among clonazepam studies the frequency of AEs was higher than
placebo by nearly 50%; with pregabalin, less than 30%. We didn’t found any head-
to-head studies with pregabalin and clonazepam and no statistical difference in anxiety 
level reduction was distinguished between drugs, WMD in HAM-A: 1.2(CI95% 1.13, 
3.54). However, clonazepam showed higher AE rates than pregabalin in somnolence 
(OR 0.54; 95%CI 0.44–0.66), headache (OR 0.50; 0.34–0.74), blurred vision (OR 
0.36; 0.13–0.98) and cognitive impairment (OR 0.25; 0.09–0.72). CONCLUSIONS:
Clonazepam and pregabalin are effective in diminishing anxiety levels in several
anxiety disorders, although clonazepam seems to cause a higher frequency of AEs.
MENTAL HEALTH – Cost Studies
PMH14
BUDGETARY IMPACT OF WELL DIRECTED USE OF PALIPERIDONE ER IN
GERMANY
Sindern J1, Mehnert A2, Schroeder-Bernhardi D3
1Janssen-Cilag GmbH, Neuss, Germany, 2Janssen-Cilag GmbH, Neuss, NRW, Germany, 3IMS 
Health GmbH & Co. OHG, Frankfurt/Main, Hessen, Germany
OBJECTIVES: Purpose of this analysis was to quantify the subgroup of schizophrenia
patients with potential treatment beneﬁ ts associated with the oral atypical antipsy-
chotic Paliperidone ER (PER) according to its clinical proﬁ le (limited liability for 
hepatic drug-drug interactions (DDI) via CYP450) and to assess the budgetary impact
of targeted use of PER for treatment of these patients. METHODS: In a retrospective 
study of longitudinal patient data from Germany using IMS Disease Analyzer, medical
records from patients with at least one diagnosis of schizophrenia (ICD10 F20-F29) 
between July 2007 and June 2008 were analyzed. For the last quarter of the study 
period prescriptions of antipsychotic and concomitant medication of schizophrenia 
